Literature DB >> 402036

Herpes simplex keratitis.

P S Binder.   

Abstract

This article reviews the current concepts for the diagnosis and treatment of Herpes simplex keratitis and its complications, discussing characteristics of the virus, the prevalence of the disease, chemical and clinical differentiation between Types I and II Herpesvirus hominis, and the many clinical presentations of Type I disease. The antiviral agents commonly in use are reviewed, covering the historical development of the drugs, indications for their use and the associated toxic and untoward reactions. An outline for the medical treatment of the different forms of Herpes simplex keratitis is given, as well as the indications for surgical intervention in the treatment of the disease. The surgical complications and results following keratoplasty are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402036     DOI: 10.1016/0039-6257(77)90113-8

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  10 in total

1.  Genotyping of herpes simplex viruses by polymerase chain reaction.

Authors:  H Piiparinen; A Vaheri
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Petros E Carvounis; Muhamet Kivilcim; Min Ren; Jonathan C Lake; Patricia Chévez-Barrios
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

3.  Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides.

Authors:  Radeekorn Akkarawongsa; Terra B Potocky; Emily P English; Samuel H Gellman; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

4.  Immune cells in a case of postherpetic marginal trophic ulcer.

Authors:  K Geboes; A Abu el-Asrar; L Missotten
Journal:  Br J Ophthalmol       Date:  1989-03       Impact factor: 4.638

5.  An M2 Rather than a TH2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.

Authors:  Dhong Hyun Lee; Homayon Ghiasi
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

6.  T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis.

Authors:  R Sciammas; P Kodukula; Q Tang; R L Hendricks; J A Bluestone
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

7.  Enzyme immunofiltration technique for rapid diagnosis of herpes simplex virus eye infections in a rabbit model.

Authors:  P H Cleveland; D D Richman; D C Redfield; D R Disharoon; P S Binder; M N Oxman
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

8.  Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice.

Authors:  Kevin R Mott; Catherine J Bresee; Sariah J Allen; Lbachir BenMohamed; Steven L Wechsler; Homayon Ghiasi
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

9.  Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1.

Authors:  H Ghiasi; S L Wechsler; R Kaiwar; A B Nesburn; F M Hofman
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis.

Authors:  P C Maudgal; L Missotten; E De Clercq; J Descamps; E De Meuter
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.